Cargando…
Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
(1) Background: The authors present the first results of active raster-scanned carbon ion radiotherapy (CIRT) for radioresistant laryngeal malignancies regarding efficacy and toxicity. (2) Methods: 15 patients with laryngeal adenoid cystic carcinoma (ACC; n = 8; 53.3%) or chondrosarcoma (CS; n = 7;...
Autores principales: | Akbaba, Sati, Lang, Kristin, Held, Thomas, Bulut, Olcay Cem, Mattke, Matthias, Uhl, Matthias, Jensen, Alexandra, Plinkert, Peter, Rieken, Stefan, Herfarth, Klaus, Debus, Juergen, Adeberg, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211114/ https://www.ncbi.nlm.nih.gov/pubmed/30340397 http://dx.doi.org/10.3390/cancers10100388 |
Ejemplares similares
-
Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety
por: Akbaba, Sati, et al.
Publicado: (2019) -
Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control
por: Akbaba, Sati, et al.
Publicado: (2019) -
Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
por: Akbaba, Sati, et al.
Publicado: (2019) -
Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
por: Held, Thomas, et al.
Publicado: (2019) -
Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience
por: Akbaba, Sati, et al.
Publicado: (2019)